Clinical trials: High Grade Myelodysplastic Syndrome Lesions
High Grade Myelodysplastic Syndrome Lesions
Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes
Patients will receive escalating doses of ldarubicin combined to Azacitidine given at the FDA/EMEA approved Schedule and dosing.
- Trial name
- NCT01305135
- Testing
- azacitidine and idarubicin
- Where
- 32 sites in France, Tunisia
- Volunteers
- 41 people
- Sponsor
- Groupe Francophone des Myelodysplasies